Amgen stands by rare disease drug Tavneos amid Japan liver toxicity report
The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning doctors against writing new prescriptions. Still, Amgen remains resolute in ...
May 18, 2026 02:21 PM EDT PharmaFDA+Marketing Amgen stands by Tavneos, despite reports of 20 deaths in Japan Andrew Dunn Senior Biopharma Correspondent The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning … Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that